PCN163 Acute Healthcare Utilization and Costs After Initiating First-line Targeted Therapy for Metastatic Lung Cancer in the US

2021 ◽  
Vol 24 ◽  
pp. S50
Author(s):  
Y. Jin ◽  
B. Yang
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Healthcare Utilization ◽  
Metastatic Lung Cancer ◽  
First Line ◽  
The Us ◽  
Metastatic Lung ◽  
Acute Healthcare

Factors associated with time to targeted therapy for patients with metastatic lung cancer with driver mutations.

2020 ◽  
Vol 38 (29_suppl) ◽  
pp. 120-120
Author(s):  
Suwei Wang ◽  
Hu Huang ◽  
Elisabeth Scheufele ◽  
Yull Edwin Arriaga ◽  
Gretchen Purcell Jackson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Liver Disease ◽  
Targeted Therapy ◽  
Targeted Therapies ◽  
Initial Diagnosis ◽  
Driver Mutations ◽  
Tumor Biomarker ◽  
Metastatic Lung Cancer ◽  
Factors Associated ◽  
Metastatic Lung

120 Background: Targeted therapies are superior to chemotherapy in metastatic lung cancer with driver gene mutations. Delays in initiation of targeted therapies may result in faster symptom progression, decline in quality of life, and shortened survival. We examined factors associated with time to initiation of targeted therapy (TTT) in patients with metastatic lung cancer with selected driver mutations. Methods: In this retrospective cohort study, IBM MarketScan claims data was used to identify patients who had an initial diagnosis of metastatic lung cancer, defined as continuous insurance enrollment 12 months pre- to 6 months post-diagnosis, with tumor biomarker (i.e., EGFR, ALK, ROS1, BRAF V600E, NTRK)-directed targeted therapy performed within 6 months of the initial diagnosis, during the timeframe of 1/1/2013 to 12/31/2018. Trends in TTT were evaluated with Wilcoxon–Mann–Whitney. Quantile regression, a robust model that analyzed factors on different outcome-related quantiles, was used to identify associations among TTT and covariates including age, sex, comorbidity, insurance type, and US region. Results: Among 8977 patients identified with an initial diagnosis of metastatic lung cancer, 710 (7.9%) received targeted therapies within the 6-month timeframe, and 1040 (12%) had tumor biomarker testing performed. The overall median TTT was 21 days (IQR = 36 days). Median TTT decreased from 25 days in 2013 to 18 days in 2018 (p = 0.03). Factors associated with longer TTT (median, 50% quantile) were increasing age (p = 0.04), cardiovascular disease (“CVD”, p = 0.03), HIV (p = 0.04), and mild liver disease (p = 0.05). For the lower quantile ( < = 1 day, 5% quantile), female sex (p = 0.01), HIV (p = 0.04), and mild liver disease (p = 0.002) were associated with longer TTT. Having a PPO health plan extended TTT (p = 0.05) at the upper quantile (79 days, 90% quantile). Conclusions: Our study showed an encouraging 5-year trend of the median TTT decreasing by 28%. Numerous factors associated with longer TTT included increasing age, CVD, HIV, mild liver disease, female sex, and PPO plan. This study provides insights into patient-related factors associated with longer time to initiation of targeted therapies for patients with metastatic lung cancer with driver mutations. Additional research is needed to identify the reasons for longer TTT and to develop strategies to expedite delivery of optimal therapies.

Tertiary amine mediated targeted therapy against metastatic lung cancer

2016 ◽  
Vol 241 ◽  
pp. 81-93 ◽  
Author(s):  
Meiling Zhou ◽  
Jianbo Li ◽  
Chunhong Li ◽  
Ling Guo ◽  
Xinyi Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Tertiary Amine ◽  
Metastatic Lung Cancer ◽  
Metastatic Lung

scholarly journals Comparison Between Drug Costs for the Systemic Treatment of Metastatic Lung Cancer, Overall Survival Gain and Economic Growth in Brazil

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 73s-73s
Author(s):  
G. Vinicius ◽  
S. Stefani ◽  
V. Lorandi ◽  
P. Rafaela ◽  
M. Souza ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Economic Growth ◽  
Overall Survival ◽  
Median Overall Survival ◽  
Single Agent ◽  
Metastatic Lung Cancer ◽  
First Line ◽  
First Line Therapy ◽  
Metastatic Lung ◽  
Platinum Doublet

Background: Systemic treatment of patients with metastatic lung cancer is considered a major advancement in the field of oncology. Although undeniable progress has been made in the treatment of such patients, affordability of the more recently implemented treatments, for people in the less developed parts of the world has been questioned. Aim: To expose the disparity between cancer drugs costs, survival gain and economic growth in a developing country (Brazil), using first line therapy to metastatic lung cancer (nonsquamous only without driver mutations) as an example. Methods: First we analyzed the costs of all included first-line systemic therapy regimens from NCCN guidelines for metastatic lung cancer (nonsquamous and no driver mutation identified) over the last two decades, dividing the therapy in five broad categories, each one corresponding to a “generation” of treatment. The following regimens were considered: single-agent chemotherapy (cisplatin), first-generation platinum doublet (cisplatin/carboplatin + etoposide), second-generation platinum doublet (cisplatin/carboplatin + vinorelbine/gemcitabine/docetaxel/paclitaxel), third-generation platinum doublet (cisplatin/carboplatin + pemetrexed) and immunotherapy (pembrolizumab). After that, we identified in the pivotal studies, how much median overall survival cumulative gain was obtained in each generation of treatment in comparison with the last one. Then we compiled the data and compared, in graphics, with economic metrics observed for Brazil during the same period, such as nominal gross domestic product (GDP) growth, GDP per capita and inflation. Results: It was observed that the current choice of first line therapy for metastatic nonsquamous lung cancer, without driver mutation: cisplatin + pemetrexed or immunotherapy (for patients with high PD-L1 expression), now costs more than 130 to 200 times the price of single-agent cisplatin. Median overall survival has been increased from 4-6 months to around 10-12 months (all patients considered) or 30 months (for patients with high PD-L1 expression), with small incremental gains for each generation of treatment. In comparison, Brazilian GDP had an increase of 85% during the same time span, while GDP per capita increased 45%. Conclusion: The exponential rising in the price of the drugs surpassed much of the economic growth of Brazil in the last two decades. Although the observed median overall survival has been steadily increasing during the same time span, reaching now an impressive mark of 30.2 months (for patients with a high level of PD-L1 expression), it is not in the same pace as the cost of the drugs. This provides major questions about affordability and access to such treatments, especially in developing countries with larger populations, even if their economy is rapidly growing.

scholarly journals Progress in anti-HER2 targeted therapy of metastatic lung cancer

2021 ◽  
Vol 271 ◽  
pp. 03074
Author(s):  
Xian Xiao ◽  
Yingjie Jia
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Malignant Tumors ◽  
Treatment Options ◽  
Research Progress ◽  
Metastatic Lung Cancer ◽  
High Incidence ◽  
Metastatic Lung ◽  
High Incidence Rate

Lung cancer is one of the most common malignant tumors in the world and one of the main causes of cancer death. In lung cancer, metastatic stage accounted for a large percentage. It is a global disease affecting human health, with high incidence rate, low malignant degree and other characteristics. After decades of exploration, anti-HER2 targeted therapy in breast has made breakthrough progress, obtained encouraging clinical efficacy, and fully improved the quality of the life of patients. Because of this, more and more researchers are focusing on anti-HER2 in metastatic lung cancer targeting research. For the past few years, new targeted drugs have been constantly developed for anti-HER2 in metastatic lung cancer, and promising data results have been obtained in clinical trials and cohort study. This article provides a review of the clinical research progress of anti-HER2 targeted therapy in metastatic lung cancer in recent years, with a view to further guiding clinical treatment and providing more treatment options for patients.

scholarly journals CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS

2020 ◽  
Vol 19 (4) ◽  
pp. 132-137
Author(s):  
N. V. Mitiushkina ◽  
I. A. Stepanov ◽  
D. O. Yurlov ◽  
E. A. Filippova ◽  
S. V. Odintsova ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Clinical Efficacy ◽  
Metastatic Lung Cancer ◽  
Metastatic Lung

scholarly journals Metastatic lung cancer in the age of targeted therapy: improving long-term survival

2016 ◽  
Vol 5 (6) ◽  
pp. 727-730 ◽  
Author(s):  
Jaydira Del Rivero ◽  
Lindsey Enewold ◽  
Anish Thomas
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Metastatic Lung Cancer ◽  
Term Survival ◽  
Long Term Survival ◽  
Metastatic Lung
Sign in / Sign up

Export Citation Format

Share Document